Drug for contrast-enhanced ultrasound examination: new dimension in early diagnosis of angionephrosclerosis in patients with type 2 diabetes on non-alcoholic fatty liver disease background

Abstract

Objective. To evaluate the diagnostic efficiency of the contrast-enhanced third-generation agent in the detection of angionephrosclerosis in patients with type 2 diabetes and non-alcoholic fatty liver disease background.Materials and methods. 26 patients (9 men and 17 women; mean age 61.5 ± 4.3 years) with a confirmed diagnosis of type 2 diabetes mellitus and NAFLD were examined. All patients underwent complex diagnostics, including: quantitative ultrasound steatometry of the liver in the framework of combined elastography with visual and quantitative assessment of the attenuation coefficient of the ultrasonic wave; ultrasound examination of the kidneys in B-mode with vascular diagnostics in the Doppler mapping mode. Also, all patients underwent contrast-enhanced ultrasound examination of the kidneys with the contrast agent for the diagnosis of angionephrosclerosis.Results. The method of CEUS of the kidneys with patients with type 2 diabetes and NAFLD has sensitivity of 92.7 %, and accuracy of 90.4 %. Color Doppler mode has sensitivity of 66.5–81.4 %, and accuracy of 58.4–73.6 %.Conclusion. The ultrasound contrast agent may be used in the early diagnosis of angionephrosclerosis in patients with type 2 diabetes and NAFLD as a non-alternative imaging method with no radiation exposure and no nephrotoxicity.